Cytokines in the pathogenesis of cancer cachexia

Current Opinion in Clinical Nutrition and Metabolic Care

Volumn 6, Issue 4, 2003, Pages 401-406

  Argilés, Josep M ^a   Busquets, Sílvia ^a   López Soriano, Francisco J ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Cancer cachexia; Cytokines; Mediators; Metabolic changes; Muscle wasting

Indexed keywords

ADENOSINE TRIPHOSPHATE; ALPHA INTERFERON; CORTICOTROPIN RELEASING FACTOR; CYTOKINE; CYTOKINE RECEPTOR ANTAGONIST; DNA; GAMMA INTERFERON; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 15; INTERLEUKIN 4; INTERLEUKIN 6; LEPTIN; LEUKEMIA INHIBITORY FACTOR; NEUROPEPTIDE Y; PENTOXIFYLLINE; ROLIPRAM; SURAMIN; THALIDOMIDE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR; UNCOUPLING PROTEIN 1; UNCOUPLING PROTEIN 2; UNCOUPLING PROTEIN 3;

ANEMIA; ANOREXIA; APOPTOSIS; ASTHENIA; CACHEXIA; CANCER; COLON ADENOCARCINOMA; FOOD INTAKE; HUMAN; HYPERMETABOLISM; LARGE CELL LYMPHOMA; LEWIS CARCINOMA; LIPOLYSIS; MALIGNANT MESOTHELIOMA; MALNUTRITION; MUSCLE ATROPHY; NONHUMAN; PATHOGENESIS; PROTEIN DEGRADATION; REVIEW; STARVATION; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TUMOR GROWTH; WEIGHT REDUCTION;

CACHEXIA; CYTOKINES; HUMANS; INTERLEUKIN-6; NEOPLASMS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 1642326631     PISSN: 13631950     EISSN: None     Source Type: Journal    
DOI: 10.1097/00075197-200307000-00008     Document Type: Review

References (44)

1. Fearon K, Moses A. Cancer cachexia. Int J Cardiol 2002; 85:73-81.
2. Costelli P, Baccino FM. Cancer cachexia: from experimental models to patient management. Curr Opin Clin Nutr Metab Care 2000; 3:177-181.
3. López-Soriano J, Carbó N, López-Soriano FJ, et al. Leptin and tumour growth in the rat. Int J Cancer 1999; 81:726-729.
4. Sato T, Meguid MM, Miyata G, et al. Does leptin really influence cancer anorexia? Nutrition 2002; 18:82-83.
5. Kowalczuk A, Wiecek A, Franek E, Kokot F. Plasma concentration of leptin, neuropeptide Y and tumor necrosis factor alpha in patients with cancers, before and after radio- and chemotherapy. Pol Arch Med Wewn 2001; 106:657-668.
6. Tessitore L, Vizio B, Jenkins O, et al. Leptin expression in colorectal and breast cancer patients. Int J Mol Med 2000; 5:421-426.
7. Brown DR, Berkowitz DE, Breslow MJ. Weight loss is not associated with hyperleptinemia in humans with pancreatic cancer. J Clin Endocrinol Metab 2001; 86:162-166. A very interesting contribution clearly demonstrating that in humans weight loss in pancreatic cancer patients is not associated with high leptin levels.
8. Aleman MR, Santolaria F, Batista N, et al. Leptin role in advanced lung cancer: a mediator of the acute phase response or a marker of the status of nutrition? Cytokine 2002; 19:21-26.
9. Mantovani G, Maccio A, Mura L, et al. Serum levels of leptin and proinflammatory cytokines in patients with advanced-stage cancer at different sites. J Mol Med 2000; 78:554-661.
10. Mantovani G, Maccio A, Madeddu C, et al. Serum values of proinflammatory cytokines are inversely correlated with serum leptin levels in patients with advanced stage cancer at different sites. J Mol Med 2001; 79:406-414.
11. Plata-Salaman CR. Central nervous system mechanisms contributing to the cachexia-anorexia syndrome. Nutrition 2000; 16:1009-1012.
12. Chance WT, Balasubramaniam A, Dayal R, et al. Hypothalamic concentration and release of neuropeptide Y into microdialysates is reduced in anorectic tumor-bearing rats. Life Sci 1994; 54:1869-1874.
13. King PJ, Widdowson PS, Doods H, Williams G. Effect of cytokines on hypothalamic neuropeptide Y release in vitro. Peptides 2000; 21:143-146.
14. Laviano A, Russo M, Freda F, Rossi-Fanelli F. Neurochemical mechanisms for cancer anorexia. Nutrition 2002; 18:100-105.
15. Bing C, Taylor S, Tisdale MJ, Williams G. Cachexia in MAC16 adenocarcinoma: suppression of hunger despite normal regulation of leptin, insulin and hypothalamic neuropeptide Y. J Neurochem 2001; 79:1004-1012. This paper shows that in the MAC16 tumor model anorexia is not associated with changes in different humoral mediators such as leptin or neuropeptide Y.
16. Strassmann G, Fong M, Freter CE, et al. Suramin interfers with interleukin-6 receptor binding in vitro and inhibits colon-26-mediated experimental cancer cachexia in vivo. J Clin Invest 1993; 92:2152-2159.
17. Barton BE, Cullison J, Jackson J, Murphy T. A model that reproduces syndromes associated with human multiple myeloma in nonirradiated SCID mice. Proc Soc Exp Biol Med 2000; 223:190-197.
18. Barton BE, Murphy TF. Cancer cachexia is mediated in part by the induction of IL-6-like cytokines from the spleen. Cytokine 2001; 16:251-257. Interesting investigation supporting the involvement of IL-6-like cytokines from the host.
19. Negri DR, Mezzanzanica D, Sacco S, et al. Role of cytokines in cancer cachexia in a murine model of intracerebral injection of human tumours. Cytokine 2001; 15:27-38.
20. Matthys P, Heremans H, Opdenakker G, Billiau A. Anti-interferon-γ antibody treatment, growth of Lewis lung tumours in mice and tumour-associated cachexia. Eur J Cancer 1991; 27:182-187.
21. Henderson JT, Mullen BJ, Roder JC. Physiological effects of CNTF-induced wasting. Cytokine 1996; 8:784-793.
22. Wang MC, Forsberg NE. Effects of ciliary neurotrophic factor (CNTF) on protein turnover in cultured muscle cells. Cytokine 2000; 12:41-48.
23. Busquets S, Sanchis D, Alvarez B, et al. In the rat, TNF-α administration results in an increase in both UCP2 and UCP3 mRNAs in skeletal muscle: a possible mechanism for cytokine-induced thermogenesis? FEBS Lett 1998; 440:348-350.
24. Puigserver P, Rhee J, Lin J, et al. Cytokine stimulation of energy expenditure through p38 MAP kinase activation of PPARgamma coactivator-1. Mol Cell 2001; 8:971-982.
25. Argilés JM, López-Soriano FJ. Catabolic proinflammatory cytokines. Curr Opin Clin Nutr Metab Care 1998; 1:245-251.
26. Chen S, Guttridge DC, Tang E, et al. Suppression of tumor necrosis factor-mediated apoptosis by nuclear factor κB-independent bone morphogenetic protein/smad signaling. J Biol Chem 2001; 42:39259-39263.
27. Guttridge DC, Mayo MW, Madrid LV, et al. NF-κB-induced loss of MyoD messenger RNA: possible role in muscle decay and cachexia. Science 2000; 289:2363-2366.
28. Kawamura I, Morishita R, Tomita N, et al. Intratumoral injection of oligonucleotides to the NFκB binding site inhibits cachexia in a mouse tumor model. Gene Ther 1999; 6:91-97.
29. Bossola M, Muscaritoli M, Costelli P, et al. Increased muscle ubiquitin mRNA levels in gastric cancer patients. Am J Physiol Regul Integr Comp Physiol 2001; 280:R1518-R1523. A very interesting contribution suggesting that the ubiquitin-dependent proteolytic pathway is responsible for muscle proteolysis in gastric cancer patients.
30. Baracos VE. Regulation of skeletal-muscle-protein turnover in cancer-associated cachexia. Nutrition 2000; 16:1015-1018.
31. Alvarez B, Quinn LS, Busquets S et al. Tumor necrosis factor-alpha exerts interleukin-6-dependent and -independent effects on cultured skeletal muscle cells. Biochim Biophys Acta 2002; 1542:66-72. This paper suggests that some of the effects of TNF on cultured muscle cells are dependent on IL-6.
32. Sharma R, Anker SD. Cytokines, apoptosis and cachexia: the potential for TNF antagonism. Int J Cardiol 2002; 85:161-171. A nice update on the role of cytokines in cachexia.
33. van Royen M, Carbó N, Busquets S, et al. DNA fragmentation occurs in skeletal muscle during tumor growth: a link with cancer cachexia? Biochem Biophys Res Commun 2000; 270:533-537.
34. Belizario JE, Lorite MJ, Tisdale MJ. Cleavage of caspases-1, -3, -6, -8 and -9 substrates by proteases in skeletal muscles from mice undergoing cancer cachexia. Br J Cancer 2001; 84:1135-1140. This investigation reveals the involvement of caspases in the apoptotic process observed in skeletal muscle during experimental cancer cachexia.
35. Carbó N, Busquets S, van Royen M, et al. TNF-α is involved in activating DNA fragmentation in murine skeletal muscle. Br J Cancer 2002; 86:1012-1016. An elegant paper demonstrating the role of TNF in activating DNA fragmentation in skeletal muscle.
36. Peuckmann V, Fisch M, Bruera E. Potential novel uses of thalidomide: focus on palliative care. Drugs 2000; 60:273-292.
37. Costelli P, Carbó N, Tessitore L, et al. Tumor necrosis factor-α mediates changes in tissue protein turnover in a rat cancer cachexia model. J Clin Invest 1993; 92:2783-2789.
38. Reinhart K, Wiegand-Lohnert C, Grimminger F, et al. Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study. Crit Care Med 1996; 24:733-742.
39. Mori K, Fujimoto-Ouchi K, Ishikawa T, et al. Murine interleukin-12 prevents the development of cancer cachexia in a murine model. Int J Cancer 1996; 67:849-855.
40. Quinn LS, Haugk KL, Grabstein KH. Interleukin-15: a novel anabolic cytokine for skeletal muscle. Endocrinology 1995; 136:3669-3672.
41. Carbó N, López-Soriano J, Costelli P, et al. Interleukin-15 antagonizes muscle protein waste in tumour-bearing rats. Br J Cancer 2000; 83:526-531.
42. Okamoto T. NSAID zaltoprofen improves the decrease in body weight in rodent sickness behavior models: proposed new applications of NSAID. Int J Mol Med 2002; 9:369-372. An interesting therapeutic approach for cachexia in experimental models.
43. Niu Q, Li T, Liu A. Cytokines in experimental cancer cachexia. Zhonghua Zhong Liu Za Zhi 2001; 23:382-384.
44. Cahlin C, Korner A, Axelsson H, et al. Experimental cancer cachexia: the role of host-derived cytokines interleukin (IL)-6, IL-12, interferon-gamma, and tumor necrosis factor alpha evaluated in gene knockout, tumor-bearing mice on C57 B1 background and eicosanoid-dependent cachexia. Cancer Res 2000; 60:5488-5493.